Fox Jennifer Lynne
Known title: Chief Legal OfficerCIK: 0001914879
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
EBS Shares Rise 14.4% After Russia Plague Lab Worker Death. EBS stock jumped 14.4% following the death of a Russian plague laboratory worker, a move that also lifted other vaccine makers such as Novavax, Arcturus and Moderna. The rally has drawn attention from retail traders who are looking for potential contract awards. The shares are currently trading near the $7.98 support level, which has been tested 20 times, and the RSI sits at 55.1, indicating neither overbought nor oversold conditions.
Transaction History
| MYGN | ▼ Sell | Tax Withholding | 4,398 | $14K | 9/3/2026 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 5,995 | $28K | 3/13/2026 | View on chart |
| MYGN | ▲ Buy | Grant | 195,876 | $0 | 3/12/2026 | View on chart |
| MYGN | ▼ Sell | Tax Withholding | 4,435 | $30K | 9/3/2025 | View on chart |
| MYGN | ▲ Buy | Grant | 63,145 | $0 | 3/13/2025 | View on chart |
| MYGN | ▲ Buy | Grant | 61,771 | $0 | 9/3/2024 | View on chart |
| EBS | ▲ Buy | Grant | 15,000 | $0 | 7/11/2024 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 2,376 | $15K | 6/8/2024 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 703 | $2K | 3/1/2024 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 4,103 | $13K | 2/29/2024 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 229 | $627 | 2/23/2024 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 413 | $826 | 11/11/2023 | View on chart |
| EBS | ▲ Buy | Grant | 24,616 | $0 | 6/9/2023 | View on chart |
| EBS | ▲ Buy | Grant | 49,231 | $0 | 6/9/2023 | View on chart |
| EBS | ▲ Buy | Grant | 6,154 | $0 | 3/2/2023 | View on chart |
| EBS | ▲ Buy | Grant | 12,308 | $0 | 3/2/2023 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 1,005 | $12K | 2/28/2023 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 258 | $4K | 2/24/2023 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 231 | $3K | 2/23/2023 | View on chart |
| EBS | ▲ Buy | Grant | 14,045 | $0 | 12/9/2022 | View on chart |
| EBS | ▲ Buy | Grant | 42,135 | $0 | 12/9/2022 | View on chart |
| EBS | ▼ Sell | Tax Withholding | 416 | $6K | 11/11/2022 | View on chart |
| EBS | ▲ Buy | Grant | 7,583 | $0 | 3/1/2022 | View on chart |
| EBS | ▲ Buy | Grant | 17,794 | $0 | 3/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis
An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis. An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.